Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf administration by LISA versus conventional brief invasive ventilation in preterm neonates with respiratory distress syndrome
2016-001974-14Phase 3
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Main Safety Outcome.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2016-001974-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001974-14.